The artificial pancreas can help protect very young children with Type 1 Diabetes
Members of the Hovorka Group teamed with an international team of researchers have compared the performance, in children, of the artificial pancreas against ‘sensor-augmented pump therapy’. The artificial pancreas uses an algorithm run by a mobile phone app (CamAPS FX) to automate delivery of insulin according to need. They found that it is both safe to use and more effective at managing their blood sugar levels than current technology. The research is published in the New England Journal of Medicine.
CamAPS FX has been shown to work in older children and adolescents with type 1 diabetes. Today’s study is the first time that it has been shown to be effective over several months in very young children. Management of type 1 diabetes is challenging in very young children for several reasons including high variability in levels of insulin required and unpredictable eating and activity patterns. Children are particularly at risk of dangerously low and high blood sugar levels, which can lead to adverse outcomes.
Current technology – sensor-augmented pump therapy – requires parents to review their child’s glucose levels using a monitor and then manually adjust the amount of insulin administered by the pump. These devices have proved successful to an extent in older children, but not in very young children.
On average, children spent around three-quarters of their day (71.6%) in the target range for their glucose levels when using CamAPS FX – an additional 125 minutes per day in the target range compared to those using the currently available approach.
Release date: 20 January 2021
Source: University of Cambridge